- Home
- Companies
- BioLingus AG
- Articles
- Project - Sublingual insulin+ (fixed ...
Project - Sublingual insulin+ (fixed dose combination product of insulin and exenatide/liraglutide)
Courtesy of BioLingus AG
The global human insulin market is projected to surpass USD 40 Billion USD. Our sublingual “insulin+” product will be positioned in a particular segment of this market : it will be prescribed for type II diabetes patients, who do not respond sufficiently to GLP-1 analogues alone.
Such a fixed dose combination is already on the market under the brand name Xultophy, which is a combination of insulin degludec and liraglutide injection.
Advantages of an insulin+ product over pure insulin are as follows :
- More stable blood glucose lowering
- Less risk of unacceptable variations and insulin overshoot
-
Most popular related searches
Customer comments
No comments were found for Project - Sublingual insulin+ (fixed dose combination product of insulin and exenatide/liraglutide). Be the first to comment!